

Bacteriostatic Potency of Fe₂O₃ Against *Enterococcus faecalis* in Synergy with Antibiotics by DDST Method

Erfan Shahbazi¹, Firouzeh Morshedzadeh², and Davood Zaeifi^{3*}

1. Department of Microbiology, Shahid Beheshti University, Tehran, Iran

2. Department of Cell and Molecular Biology, University of Tehran, Tehran, Iran

3. Department of Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran

Abstract

Background: In this study, bacteriostatic potency of the Iron oxide nanoparticles against *Enterococcus faecalis* (*E. faecalis*) (a clinical sample and the ATCC11700 strain) was investigated.

Methods: Nanoparticles' bacteriostatic concentration was determined and used to appraise the characteristics of the Iron Oxide (Fe₂O₃) against the isolates. Antimicrobial examinations with 10⁸ cfu.ml⁻¹ were performed at the baseline. Due to evaluation level of potency, after performing Minimum Inhibitory Concentration (MIC), the assessment of death kinetic and susceptibility constant of nanoparticles was done by suspension at two MICs in 0 to 360 min treatment time.

Results: Fe₂O₃ nanoparticles in size range of 10–50 nm demonstrated the most effective susceptibility reaction against *E. faecalis* and ATCC11700 strain in Z=78.125 ml/μg⁻¹ and 39.0625 ml/μg⁻¹, respectively. The kinetic reaction of *E. faecalis* against Fe₂O₃ suspension was supposed to be decreased through the elapse of treatment time, whereas increased concentration was along with bacteria growth after a certain time. So, the efficient concentration of nanoparticles was applied with semi-sensitive and antibiotic resistant for both strains. However, synergism of Fe₂O₃ nanoparticles with Cefazidime and Clindamycin revealed a higher susceptibility compared with Fe₂O₃ nanoparticles alone against *E. faecalis*.

Conclusion: The experimental results reveal that Fe₂O₃ has a strong antimicrobial effect at a certain concentration over the time so could potentially be used for bacterial inhibition and this feature will be strengthened in combination with antibiotics.

Avicenna J Med Biotech 2019; 11(2): 176–179

Keyword: *Enterococcus faecalis*, Ferric oxide, Nanoparticles

Introduction

Enterococci are one of the most frequent causes of nosocomial infections in the intensive care unit; they appear in this sector along with clumsy use of cephalosporins and other antibiotics to which enterococci are resistant. These bacteria are contagious and usually cause infection in the urinary tract, wound, bile duct, and blood at the hospital; also, they can cause meningitis in children and endocarditis in adults^{1,2}.

Enterococcus faecalis (*E. faecalis*) is one of the most common species of *enterococcus* which causes 85 to 90% of enterococcal infections. Gram-positive bacteria were previously classified as Group D *Streptococcus*, due to specific antigen which is teichoic acid. Most of these bacteria are non-hemolytic and sometimes are alpha-hemolytic which can be found in natural intestinal flora¹⁻⁴.

These bacteria are resistant to many antibiotics like Meropenem, Gentamicin, Ceftriaxone, Cefazidime,

Cefixime, Trimethoprim/Sulfamethoxazole, Erythromycin, and Clindamycin with above 60% resistance frequency rate and sensitivity to Vancomycin, Teicoplanin, and Nitrofurantion based on report³⁻⁹.

Iron oxide due to its biocompatibility and magnetic feature has been widely used in biomedical research^{10,11}. Nanoparticles (NP) of Iron oxide with certain sizes (almost less than 100 nm), are applied for targeted drug delivery as carriers for many types of cancer^{12,13}. Moreover, nanoparticles are used for drug delivery system which were extended for directing nanoparticles by using an external magnetic field in particular places due to accurate treatment¹⁴. Therefore, it is assumed that Reactive Oxygen Species (ROS) produced by nanoparticles have a bacteriostatic potency without damaging eukaryotic cells^{15,16}.

The aim of this study was to find a way to prevent drug resistance by using lower doses of antibiotics to

* Corresponding author:
Davood Zaeifi, Ph.D.,
Department of Biology, Tehran
North Branch, Islamic Azad
University, Tehran, Iran
Tel: +98 21 22946018
Fax: +98 21 77009848
E-mail: d.zaeifi@ut.ac.ir
Received: 31 Dec 2017
Accepted: 10 Mar 2018

treat the bacterial infections.

Materials and Methods

The reference strain, *E. faecalis* (ATCC 11700), was used as the control strain in all steps for comparison purposes.

Preparation of culture medium

In total, 20 culture-positive specimens of *E. faecalis* were collected from patients at Tehran University of Medical Sciences and cultured on Bile Esculin Agar (Merck, Germany) ^{17,18}.

Kirby-Bauer Susceptibility Test

In order to test the resistance of *E. faecalis*, clinical-positive specimens of these bacteria were cultured on Mueller Hinton agar medium (Merck, Germany). Disk diffusion was performed using Kirby-Bauer method (Clindamycin 2 μg , Oxacillin 1 μg , Erythromycin 15 μg , Cefotaxime 30 μg , Ceftazidime 30 μg , Tetracycline 30 μg , Chloramphenicol 30 μg , Vancomycin 30 μg disks, Mast Group Ltd Company, UK). Incubation was performed for 24 *hr* at 37°C with 5% CO₂ (Semi-aerobic conditions). The isolate with higher resistance was selected for further study.

Preparation of nanoparticle (NP) suspension

Fe₂O₃ nanoparticles (Purity over 99.7%) with 10-50 *nm* range size were purchased from US NANO. Nanoparticles stock solution was prepared by suspending one gram of nanoparticles into 100 *ml* sterile medium and dispersion was done by Electro sonic system (Bandelier Sonorex RK 31H) for 35 *min*. The microbial tests and preparation of nanoparticle suspensions were performed simultaneously in order to reduce probable errors.

Microbial suspension preparation

At first, bacterial cells were collected from BEA culture medium and were mixed in 10 *ml* Phosphate-Buffered Saline (PBS) in order to prepare samples with 0.5 McFarland Turbidity [$1-1.5 \times 10^8$ Colony-Forming Unit (CFU)] and the accuracy was measured by spectrophotometer (UNICO-2100; USA) at 620 *nm* wavelength range and absorbance was set at the range from 0.08 to 0.1 *nm*.

MIC test and bacteriostatic potency

The Clinical and Laboratory Standards Institute

(CLSI) recommendations were used for Minimal Inhibitory Concentration (MIC) calculation of the sample in contact with the NP suspension. Gradient concentrations of Fe₂O₃NPs suspension, both NPs with bacteria, were prepared according to a conducted study by Khavarani *et al* ^{18,19}.

Nanoparticles impregnated discs preparation

Sterile blank discs (Crude) were placed in a plate, then nanoparticle suspension with desired concentration was poured into the plate, where the discs were not immersed, then incubated about 24 *hr* at room temperature until the suspension was completely absorbed by blank discs ²⁰.

DDST susceptibility test

The antibiotics to which the isolate showed resistance or semi-susceptibility were selected and assessed for DDST in Mueller Hinton agar medium with 20 *mm* center to be centered in the plate. Incubation was performed for 18 *hr* at 37°C and the inhibition zone from the edge of each disc was recorded ¹⁹.

Results

Kirby-Bauer Susceptibility Test

The isolated bacteria were resistant to Oxacillin and Ceftazidime, and semi-sensitive to Tetracycline and Chloramphenicol acid antibiotics (Table 1).

Preparation of the nanoparticle suspensions

The X-ray powder diffraction (XRD) diagram of the commercial Fe₂O₃ powder in figure 1A demonstrates the proper purity due to lack of any impurity diffraction pattern. Figure 1B presents the corresponding morphology and particle size distributions of prepared Fe₂O₃ powders by TEM microscopy.

MIC test and bacteriostatic potency

According to the results, the antimicrobial activity of Iron oxide nanoparticles suspensions against *E. faecalis*, the MIC for the isolated bacteria and ATCC-11700 strain against Iron oxide NPs were $Z=78.125 \text{ ml}/\mu\text{g}^{-1}$ and $39.0625 \text{ ml}/\mu\text{g}^{-1}$, respectively. The sensitivity coefficient for *E. faecalis* against the nanoparticle suspension was calculated for each sampling period. The mean of bacterial coefficient sensitivity to the nanoparticles is shown in figure 2.

Table 1. Sensitivity of the *E. faecalis* to the applied antibiotics and in synergy with Fe₂O₃ nanoparticles

| Antibiotic | μg | Clinical Sample | | |
|-----------------|---------------|--|---------------------------------|----------------------------|
| | | ATCC11700 Zone diameter (mm) Mast Disc | Zone diameter (mm) Mast Disc | Zone diameter (mm) DDST |
| Clindamycin | 2 | 10 | 0 | 12 |
| Oxacillin | 1 | 0 | 0 | 12 |
| Erythromycin | 15 | 25 | 23 | NA |
| Cefotaxime | 30 | 19 | 18 | NA |
| Ceftazidime | 30 | 17 | 0 | 13 |
| Tetracycline | 30 | 13 | 13 | NA |
| Chloramphenicol | 30 | 11 | 11 | 12 |
| Vancomycin | 30 | 25 | 20 | NA |

* (NA)-did not test.

Bacteriostatic Potency of Fe₂O₃ Against *Enterococcus faecalis* by DDST Method




Figure 1. A) XRD of Fe₂O₃ nanoparticles, B) TEM of the Fe₂O₃ nanoparticles.




Figure 2. *E. faecalis* population coefficient sensitivity due to the time of investigation. A) ATCC11700 (MIC after 180 min)-B) Clinical sample (MIC after 120 min).

DDST susceptibility test

The results in table 1 show higher antibacterial activity for Clindamycin, Oxacillin, and Cefotaxime due to visibility of the zone; however, it seems Chloramphenicol in synergy with the applied Fe₂O₃ did not increase the inhibitory zone significantly.

Discussion

XRD and TEM images illustrate the appropriate crystal structure of synthesized Iron oxide NPs and have almost regular spherical shape in the size range of nano. Some bacteria have the potency in reducing metal oxide by mechanisms^{15,16}, therefore reducing the size of Iron NPs would not be a good idea for increasing toxicity of metal oxide²¹; but nanoparticles with higher number of reactive groups on the surface like active sites for the formation of ROS which lead to oxidative stress could be good candidates^{15,22}.

Many studies reveal that in aquatic system, the antimicrobial activity of metal oxide compounds was mainly caused by soluble ions, and has effect on reduced cellular function due to aggregation of NPs in aqueous medium²³. But at efficient concentration, NPs at dilution condition can be more toxic for cells than the metal ionic form which is described as a nano-trojan horse type of mechanism²².

According to figure 2, NPs inhibitory properties against *E. faecalis* were enhanced by increasing nanoparticles concentration. But higher concentration of

nanoparticles leads to slight growth; so, Iron oxide nanoparticles had no bactericidal effect on tested strains.

Previous studies represent that, if the environmental pH is lower than the pH of NPs, the surface of NPs could be positively charged and vice-versa²⁴. Theoretically, the pH values of Fe₂O₃ NPs have been calculated to be 5-7. Due to lack of significant difference between both pH values (pH of microorganism is about 2-4), this opinion could not be justifiable.

The results express that Chloramphenicol in synergy with NPs could not increase inhibitory effect significantly (Table 1). According to the given explanations, surface charge of bacteria is reduced due to repulsion²⁵. Therefore, greater concentration of NPs due to this electrostatic repulsion force cannot be a suitable option to overcome this inhibitory force²⁴.

Conclusion

Based on our findings, it can be inferred that Iron oxide nanoparticles suspension in different concentrations has growth inhibitory effects against bacteria that cause nosocomial infections, but at higher concentrations than the MIC, presumably it can make adaption to Fe²⁺ ions which could be used as a source of energy in metabolic pathway.

The use of bacteriostatic potency of these NPs against bacteria suspensions with certain concentration in combination with antibiotics can be a good option

for inhibition of the bacterial infections in medical domains.

Conflict of Interest

Authors declare no conflict of interest.

References

- Hasani A, Sharifi Y, Ghotaslou R, Naghili B, Hasani A, Aghazadeh M, et al. Molecular screening of virulence genes in high-level gentamicin-resistant *Enterococcus faecalis* and *Enterococcus faecium* isolated from clinical specimens in Northwest Iran. *Indian J Med Microbiol* 2012;30(2):175-181.
- Sadeghifard N, Kazemian H, Mohebi R, Sekawi Z, Khosravi A, Valizadeh N, et al. Epidemiological alteration in pathogens found in ground meat in Iran: unexpected predominance of vancomycin-resistant *Enterococcus faecalis*. *GMS Hyg Infect Control* 2015;10:Doc12.
- Feizabadi MM, Maleknejad P, Asgharzadeh A, Asadi S, Shokrzadeh L, Sayadi S. Prevalence of aminoglycoside-modifying enzymes genes among isolates of *Enterococcus faecalis* and *Enterococcus faecium* in Iran. *Microb Drug Resist* 2006;12(4):265-268.
- Mohammadi F, Ghafourian S, Mohebi R, Taherikalani M, Pakzad I, Valadbeigi H, et al., *Enterococcus faecalis* as multidrug resistance strains in clinical isolates in Imam Reza Hospital in Kermanshah, Iran. *Br J Biomed Sci* 2015;72(4):182-184.
- Gajan EB, Abashov R, Aghazadeh M, Eslami H, Oskouei SG, Mohammadnejad D. Vancomycin-resistant *Enterococcus faecalis* from a wastewater treatment plant in Tabriz, Iran. *Pak J Biol Sci* 2008;11(20):2443-2446.
- Sharifi Y, Hasani A, Ghotaslou R, Varshochi M, Hasani A, Aghazadeh M, et al. Survey of virulence determinants among vancomycin resistant *enterococcus faecalis* and *enterococcus faecium* isolated from clinical specimens of hospitalized patients of north west of Iran. *Open Microbiol J* 2012;6:34-39.
- Khani M, Fatollahzade M, Pajavand H, Bakhtiari S, Abiri R. Increasing prevalence of aminoglycoside-resistant *enterococcus faecalis* isolates due to the *aac(6)-aph(2'')* gene: a therapeutic problem in Kermanshah, Iran. *Jundishapur J Microbiol* 2016;9(3):e28923.
- Heidari H, Hasanpour S, Ebrahim-Saraie HS, Motamedifar M. Ebrahim-Saraie. High incidence of virulence factors among clinical *enterococcus faecalis* isolates in southwestern Iran. *Infect Chemother* 2017;49(1):51-56.
- Feizabadi MM, Asadi S, Zohari M, Gharavi S, Etemadi G. Genetic characterization of high-level gentamicin-resistant strains of *Enterococcus faecalis* in Iran. *Can J Microbiol* 2004;50(10):869-872.
- Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials* 2005;26(18):3995-4021.
- Wu W, Jiang CZ, Roy VA. Designed synthesis and surface engineering strategies of magnetic iron oxide nanoparticles for biomedical applications. *Nanoscale* 2016;8(47):19421-19474.
- Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. *Langmuir* 2005;21(19):8858-8864.
- Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. *Biomaterials* 2008;29(4):487-496.
- Pareta RA, Taylor E, Webster TJ. Increased osteoblast density in the presence of novel calcium phosphate coated magnetic nanoparticles. *Nanotechnology* 2008;19(26):265101.
- Ortiz de Orué Lucana D, Wedderhoff I, Groves MR. ROS-mediated signalling in bacteria: zinc-containing cys-x-x-cys redox centres and iron-based oxidative stress. *J Signal Transduct* 2012;2012:605905.
- Cornelis P, Wei Q, Andrews SC, Vinckx T. Iron homeostasis and management of oxidative stress response in bacteria. *Metallomics* 2011;3(6):540-549.
- Barry AL, Craig WA, Nadler H, Reller LB, Sanders CC, Swenson JM. Methods for determining bactericidal activity of antimicrobial agents: approved guideline. USA: National Committee for Clinical Laboratory Standards; 1999. Vol. 19, No 18.
- Food UD. Administration, Division of Anti-infective and Ophthalmology Drug Products (HFD-520)-Microbiological data for antibacterial drug products-development, analysis, and presentation. FDA. 2005. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021821orig1s000micror.pdf.
- Fathi Azar Khavarani M, Najafi M, Shakibapour Z, Zaeifi D. kinetics activity of yersinia intermedia against ZnO nanoparticles either synergism antibiotics by double-disc synergy test method. *Iran J Biotechnol* 2016;14(1):39-44.
- Balouiri M, Sadiki M, Ibsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. *J Pharm Anal* 2016;6(2):71-79.
- Asakawa S, Bünemann E, Frossard E. Microbially Mediated Processes. In: Huang PM, Li Y, Sumner ME, editors. *Handbook of Soil Sciences*. Boca Raton, Florida: CRC Press; 2011. p. 1-52.
- Limbach LK, Wick P, Manser P, Grass RN, Bruinink A, Stark WJ. Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. *Environ Sci Technol* 2007;41(11):4158-4163.
- Wu B, Huang R, Sahu M, Feng X, Biswas P, Tang YJ. Bacterial responses to Cu-doped TiO₂ nanoparticles. *Sci Total Environ* 2010;408(7):1755-1758.
- Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. *Acta Biomater* 2008;4(3):707-716.
- Yoon KY, Hoon Byeon J, Park JH, Hwang J. Susceptibility constants of *Escherichia coli* and *Bacillus subtilis* to silver and copper nanoparticles. *Sci Total Environ* 2007;373(2-3):572-575.